ADA

Endocrinologists urged to pay attention to COORDINATE trial

But GI side effects higher than other comparable anti-obesity agents

Once-weekly CagriSema reduced body weight more than either agent alone

These were patients with "really debilitating diabetes," says investigator

Another study showed two high doses were better at reducing HbA1c vs a 14-mg dose

Plus, two other studies on retatrutide show benefit in type 2 diabetes, fatty liver disease

More positive results in CLEAR Outcomes sub-analysis

Superior to once-a-day insulin glargine U100 and degludec

Daily orforglipron also lowered HbA1c in type 2 diabetes

Noteworthy research presented at the American Diabetes Association annual meeting

Depressive symptoms and history of suicide attempts linked with higher HbA1c

Users spent more time in target glucose range than those on sensor augmented pump therapy

Steady decreases in the prevalence of patients with eye problems may be over

But clinical trial currently under FDA hold as dosing is discussed